Terug
Dagbereik
€ 61,98
€ 63,68
52-Weeksbereik
€ 32,48
€ 71,92
Volume
647.884
50D / 200D Gem.
€ 64,85
/
€ 55,98
Vorige Slotkoers
€ 63,24
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -14,1 | 0,3 |
| P/B | 2,8 | 2,9 |
| ROE % | -19,2 | 3,7 |
| Net Margin % | -17,5 | 3,8 |
| Rev Growth 5Y % | 7,6 | 10,0 |
| D/E | 0,4 | 0,2 |
Koersdoel Analisten
Hold
€ 75,88
+21.6%
Low: € 66,00
High: € 85,00
Forward K/W
15,0
Forward WPA
€ 4,21
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,5 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 6,41
€ 6,14 – € 6,53
|
1,9 B | 1 |
| FY2029 |
€ 5,81
€ 5,57 – € 5,92
|
1,8 B | 1 |
| FY2028 |
€ 5,05
€ 4,60 – € 5,50
|
1,7 B | 2 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 11, 2026 |
Poletti Franco
President, Cardiopulmonary
|
other | 6.329 | € 57,60 | — |
| Dec 15, 2025 |
Poletti Franco
President, Cardiopulmonary
|
other | 2.350 | — | — |
| Dec 15, 2025 |
Hutchinson Michael Damon
SVP, CLO and Company Secretary
|
other | 5.630 | — | — |
| Dec 15, 2025 |
PODLOGAR SUSAN M
Director
|
other | 4.979 | — | — |
| Nov 18, 2025 |
Story Brooke
Director
|
sell | 250 | € 53,94 | € 13.485 |
| Sep 15, 2025 |
Poletti Franco
President, Cardiopulmonary
|
other | 1.563 | — | — |
| Aug 25, 2025 |
Bianchi Francesco
Director
|
sell | 1.500 | € 56,50 | € 84.750 |
| Jun 15, 2025 |
Story Brooke
Director
|
other | 7.242 | — | — |
| Jun 15, 2025 |
Story Brooke
Director
|
grant | 4.042 | — | — |
| Jun 15, 2025 |
SCHERMERHORN TODD C
Director
|
other | 7.242 | — | — |
| Jun 15, 2025 |
SCHERMERHORN TODD C
Director
|
grant | 4.042 | — | — |
| Jun 15, 2025 |
KOZY WILLIAM A
Director
|
other | 10.261 | — | — |
| Jun 15, 2025 |
KOZY WILLIAM A
Director
|
grant | 5.681 | — | — |
| Jun 15, 2025 |
PODLOGAR SUSAN M
Director
|
grant | 4.042 | — | — |
| Jun 15, 2025 |
Barry James Christopher
Director
|
other | 7.242 | — | — |
| Jun 15, 2025 |
Barry James Christopher
Director
|
grant | 4.042 | — | — |
| Jun 15, 2025 |
Enxing Seng Stacy
Director
|
other | 7.242 | — | — |
| Jun 15, 2025 |
Enxing Seng Stacy
Director
|
grant | 4.042 | — | — |
| Jun 15, 2025 |
Tezel Ahmet
Chief Innovation Officer
|
other | 6.966 | — | — |
| Jun 15, 2025 |
WILVER PETER M
Director
|
other | 7.242 | — | — |
Belangrijkste Punten
Revenue grew 7,60% annually over 5 years — modest growth
Earnings declined -483,50% over the past year
Debt/Equity of 0,39 — conservative balance sheet
Generating 173,20M in free cash flow
PEG of 0,03 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,14%
Groei
Revenue Growth (5Y)
7,60%
Revenue (1Y)10,74%
Earnings (1Y)-483,50%
FCF Growth (3Y)108,26%
Kwaliteit
Return on Equity
-19,24%
ROIC8,94%
Net Margin-17,47%
Op. Margin14,36%
Veiligheid
Debt / Equity
0,39
Current Ratio1,36
Interest Coverage4,04
Waardering
P/E Ratio
-14,07
P/B Ratio2,84
EV/EBITDA16,30
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10,74% | Revenue Growth (3Y) | 9,70% |
| Earnings Growth (1Y) | -483,50% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 7,60% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,39B | Net Income (TTM) | -242,50M |
| ROE | -19,24% | ROA | -9,31% |
| Gross Margin | 67,71% | Operating Margin | 14,36% |
| Net Margin | -17,47% | Free Cash Flow (TTM) | 173,20M |
| ROIC | 8,94% | FCF Growth (3Y) | 108,26% |
| Safety | |||
| Debt / Equity | 0,39 | Current Ratio | 1,36 |
| Interest Coverage | 4,04 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -14,07 | P/B Ratio | 2,84 |
| P/S Ratio | 2,46 | PEG Ratio | 0,03 |
| EV/EBITDA | 16,30 | Dividend Yield | 0,00% |
| Market Cap | 3,41B | Enterprise Value | 3,25B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,39B | 1,25B | 1,15B | 1,02B | 1,04B |
| Net Income | -242,50M | 63,23M | 17,55M | -86,25M | -135,82M |
| EPS (Diluted) | -4,45 | 1,16 | 0,32 | -1,61 | -2,68 |
| Gross Profit | 939,90M | 870,87M | 771,25M | 707,23M | 705,99M |
| Operating Income | 199,40M | 129,05M | -68,50M | -76,75M | -784.000,0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2,61B | 2,51B | 2,43B | 2,29B | 2,20B |
| Total Liabilities | 1,41B | 1,19B | 1,15B | 1,09B | 906,31M |
| Shareholders' Equity | 1,20B | 1,32B | 1,28B | 1,21B | 1,29B |
| Total Debt | 473,30M | 676,77M | 640,40M | 580,43M | 286,70M |
| Cash & Equivalents | 635,60M | 428,86M | 266,50M | 214,17M | 207,99M |
| Current Assets | 1,10B | 1,13B | 988,16M | 886,14M | 679,18M |
| Current Liabilities | 808,10M | 392,13M | 334,98M | 297,40M | 696,97M |